Last updated on November 2017

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102


Brief description of study

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Detailed Study Description

This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase I deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing.

Clinical Study Identifier: TX15527

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

University of Florida

University of Florida
Gainesville, FL USA
  Connect »